Treating hypertension: it is not how you start but where you end that matters

Editorial

Bryan Williams. J Hypertens. 2003 Mar.

. 2003 Mar;21(3):455-7.

doi: 10.1097/01.hjh.0000052459.40108.e4.

No abstract available

Comment in

What lies behind the intense criticism of ALLHAT?
Lasaridis AN, Sarafidis PA. Lasaridis AN, et al. J Hypertens. 2004 Jan;22(1):223-4; author reply 224-7. doi: 10.1097/00004872-200401000-00033. J Hypertens. 2004. PMID: 15106815 No abstract available.

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA. 2002 Dec 18;288(23):2981-97. doi: 10.1001/jama.288.23.2981. JAMA. 2002. PMID: 12479763 Clinical Trial.